The diagnostics developer has raised £150,000 through a convertible loan note to support the rollout of its early cancer test in the UK and Europe, following a licensing deal in North America.
The diagnostics developer publishes its annual results, providing limited details on its progress in developing an early lung cancer detection test.
The diagnostics developer has secured its first contract in the Caribbean for its CIZ1B biomarker test, triggering early royalty payments and signaling progress in the commercialization of its technology.
The diagnostics developer has launched a new corporate website to provide information and updates to stakeholders.
The healthcare company has appointed a new non-executive director to strengthen its strategic and business capabilities.
The diagnostics developer has appointed a COLA accredited and CLIA certified lab in the US to launch its CIZ1B biomarker test for early-stage lung cancer detection.
The diagnostics developer has appointed a new Chief Scientific Officer and made progress on its lung cancer biomarker assay, positioning the company for potential growth.
The diagnostics developer has expanded its North American partnership to include the Caribbean, securing early royalty payments and its first accredited laboratory partner as it advances towards product launch.
Diagnostics developer Cizzle Biotechnology secures exclusive North American licensing deal for its lung cancer biomarker test, positioning the company for growth.
Diagnostics developer Cizzle Biotechnology advances its US licensing agreement, attracting significant clinical interest.